LINCOLN, Neb.--(BUSINESS WIRE)--Adjuvance Technologies announced today that it has been awarded supplemental contract funding from The National Institute of Allergy and Infectious Diseases (NIAID). The funds will be used to evaluate TQL1055, manufactured by Adjuvance, with SARS-CoV2 antigen, manufactured by NIH (National Institutes of Health). TQL1055 is Adjuvance’s novel Saponin vaccine adjuvant. The total funding in this contract is $1.47million.
“We are pleased to receive this funding from NIH and look forward to making our contribution to the global effort to develop a safe and effective COVID-19 vaccine,” said Dr. Tyler Martin, Chairman & CEO of Adjuvance. “We join more than 120 global teams from academia and industry working on this problem and expect that collaboration will yield the best solution.”
“Adjuvance, a Nebraska Innovation Campus partner, appreciates the cooperation of the University of Nebraska where preliminary experiments were conducted, and new experiments will take place.” said Dr. Martin.
About Adjuvance Technologies: Adjuvance Technologies, Inc. is a privately held biopharmaceutical company focused on improving health and saving lives through breakthroughs in vaccine adjuvant design. Its lead adjuvant, TQL1055, is in pre-clinical development for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy. More information is available at www.adjuvancetechnologies.com.
About The National Institutes of Health and The National Institute of Allergy and Infectious Diseases: The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency -- making important discoveries that improve health and save lives. The National Institute of Allergy and Infectious Diseases (NIAID) is the NIH Institute that leads research to understand, treat and prevent infectious, immunologic, and allergic disease.
